DuPont’s Ethmozine
Executive Summary
Reportedly, approval of the anti-arrhythmic moricizine is imminent. FDA's Cardio-Renal Drugs Advisory Committee recommended approval of the drug in January 1989 but only on the condition that the agency fully analyze the NIH's Cardiac Arrhythmia Pilot Study. The CAPS study involved a comparison of Ethmozine, three other drugs and placebo in treating arrhythmias in post-myocardial infarction patients. DuPont is seeking approval of its drug for treating symptomatic ventricular arrhythmias and life-threatening arrhythmias.